Page last updated: 2024-11-04

imatinib and Leukemia, Myeloid, Acute

imatinib has been researched along with Leukemia, Myeloid, Acute in 7 studies

Leukemia, Myeloid, Acute: Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's5 (71.43)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
Peng, H1
Huang, N1
Qi, J1
Xie, P1
Xu, C1
Wang, J1
Yang, C1
Page, BD1
Khoury, H1
Laister, RC1
Fletcher, S1
Vellozo, M1
Manzoli, A1
Yue, P1
Turkson, J1
Minden, MD1
Gunning, PT1
Heidary, DK1
Huang, G1
Boucher, D1
Ma, J1
Forster, C1
Grey, R1
Xu, J1
Arnost, M1
Choquette, D1
Chen, G1
Zhou, JH1
Yao, YM1
Ball, ED1
Namchuk, M1
Davies, RJ1
Henkel, G1
Romagnoli, R1
Baraldi, PG1
Prencipe, F1
Lopez-Cara, C1
Rondanin, R1
Simoni, D1
Hamel, E1
Grimaudo, S1
Pipitone, RM1
Meli, M1
Tolomeo, M1
Klaeger, S1
Heinzlmeir, S1
Wilhelm, M1
Polzer, H1
Vick, B1
Koenig, PA1
Reinecke, M1
Ruprecht, B1
Petzoldt, S1
Meng, C1
Zecha, J1
Reiter, K1
Qiao, H1
Helm, D1
Koch, H1
Schoof, M1
Canevari, G1
Casale, E1
Depaolini, SR1
Feuchtinger, A1
Wu, Z1
Schmidt, T1
Rueckert, L1
Becker, W1
Huenges, J1
Garz, AK1
Gohlke, BO1
Zolg, DP1
Kayser, G1
Vooder, T1
Preissner, R1
Hahne, H1
Tõnisson, N1
Kramer, K1
Götze, K1
Bassermann, F1
Schlegl, J1
Ehrlich, HC1
Aiche, S1
Walch, A1
Greif, PA1
Schneider, S1
Felder, ER1
Ruland, J1
Médard, G1
Jeremias, I1
Spiekermann, K1
Kuster, B1
Lin, WH1
Wu, SY1
Yeh, TK1
Chen, CT1
Song, JS1
Shiao, HY1
Kuo, CC1
Hsu, T1
Lu, CT1
Wang, PC1
Wu, TS1
Peng, YH1
Lin, HY1
Chen, CP1
Weng, YL1
Kung, FC1
Wu, MH1
Su, YC1
Huang, KW1
Chou, LH1
Hsueh, CC1
Yen, KJ1
Kuo, PC1
Huang, CL1
Chen, LT1
Shih, C1
Tsai, HJ1
Jiaang, WT1
Marín-Rubio, JL1
Peltier-Heap, RE1
Dueñas, ME1
Heunis, T1
Dannoura, A1
Inns, J1
Scott, J1
Simpson, AJ1
Blair, HJ1
Heidenreich, O1
Allan, JM1
Watt, JE1
Martin, MP1
Saxty, B1
Trost, M1

Other Studies

7 other studies available for imatinib and Leukemia, Myeloid, Acute

ArticleYear
Identification of novel inhibitors of BCR-ABL tyrosine kinase via virtual screening.
    Bioorganic & medicinal chemistry letters, 2003, Nov-03, Volume: 13, Issue:21

    Topics: Binding Sites; Computer Simulation; Databases, Genetic; Drug Evaluation, Preclinical; Enzyme Inhibit

2003
Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity.
    Journal of medicinal chemistry, 2012, Feb-09, Volume: 55, Issue:3

    Topics: Aminosalicylic Acids; Antineoplastic Agents; Binding, Competitive; Cell Line, Tumor; Drug Screening

2012
VX-322: a novel dual receptor tyrosine kinase inhibitor for the treatment of acute myelogenous leukemia.
    Journal of medicinal chemistry, 2012, Jan-26, Volume: 55, Issue:2

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Survival; fms-Like Tyrosine Kinase 3; Humans; Leukem

2012
Novel iodoacetamido benzoheterocyclic derivatives with potent antileukemic activity are inhibitors of STAT5 phosphorylation.
    European journal of medicinal chemistry, 2016, Jan-27, Volume: 108

    Topics: Antineoplastic Agents; Apoptosis; Benzofurans; Benzophenones; Cell Proliferation; Dose-Response Rela

2016
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinas

2017
Identification of a Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia.
    Journal of medicinal chemistry, 2019, 12-26, Volume: 62, Issue:24

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Female; fms-Like Tyrosine Kinase 3; G

2019
A Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Assay Identifies Nilotinib as an Inhibitor of Inflammation in Acute Myeloid Leukemia.
    Journal of medicinal chemistry, 2022, 09-22, Volume: 65, Issue:18

    Topics: Cytokines; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Inflammat

2022